Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 1635 word(s) 1635 2021-02-07 10:14:18 |
2 format correct -21 word(s) 1614 2021-02-25 09:56:20 | |
3 format -21 word(s) 1614 2021-02-25 10:04:36 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Alix-Panabieres, C. Liquid Biopsy in MCC. Encyclopedia. Available online: https://encyclopedia.pub/entry/7534 (accessed on 16 April 2024).
Alix-Panabieres C. Liquid Biopsy in MCC. Encyclopedia. Available at: https://encyclopedia.pub/entry/7534. Accessed April 16, 2024.
Alix-Panabieres, Catherine. "Liquid Biopsy in MCC" Encyclopedia, https://encyclopedia.pub/entry/7534 (accessed April 16, 2024).
Alix-Panabieres, C. (2021, February 24). Liquid Biopsy in MCC. In Encyclopedia. https://encyclopedia.pub/entry/7534
Alix-Panabieres, Catherine. "Liquid Biopsy in MCC." Encyclopedia. Web. 24 February, 2021.
Liquid Biopsy in MCC
Edit

In these last years, liquid biopsy has emerged as a candidate approach to overcome this limit and to identify biomarkers for early cancer diagnosis, prognosis, therapeutic response prediction, and patient follow-up. Liquid biopsy is a blood-based non-invasive procedure that allows the sequential analysis of circulating tumor cells, circulating cell-free and tumor DNA, and extracellular vesicles. These innovative biosources show similar features as the primary tumor from where they originated and represent an alternative to invasive solid tumor biopsy.

cancer skin cancers liquid biopsy biomarkers melanoma merkel cell carcinoma

1. Introduction

This review discusses the most recent data on liquid biopsy in patients with melanoma, the most common skin cancer with high prevalence in US and European populations [1], or Merkel Cell Carcinoma (MCC), a skin tumor with a disease-associated mortality rate even higher than that of melanoma [2]. Due to their high mortality rate, new technologies are needed to improve the patient outcome. Particularly, specific biomarkers are required to facilitate their diagnosis and management. For a long time, cancer study was based on the analysis of specimens from the primary tumor or its metastases and on imaging data. The current limitations of tumor tissue biopsies and clinical imaging for cancer diagnosis and molecular profiling have led to the development of liquid biopsy. Indeed, tumor biopsy is an invasive procedure, and tumor tissue (especially in patients with cutaneous melanoma) is not always available. Therefore, liquid biopsy, a blood-based analysis of tumor-specific biomarkers, has been introduced as a new diagnostic approach that relies on circulating tumor cells (CTCs) and on circulating tumor-derived factors, such as cell-free tumor DNA (ctDNA), microRNAs (miRNA) and exosomes. The ultimate goal of liquid biopsy is to use the information gathered from such cells and factors to predict early cancer progression and to longitudinally monitor the treatment response, for a personalized medicine of patients with cancer. In melanoma, liquid biopsy has been already used to study many biomarkers (e.g., CTCs, ctDNA and exosomes), and its clinical pertinence is currently investigated in various clinical trials. For MCC, studies are in the early days and very few articles have been published. Moreover, no clinical trial is assessing liquid biopsy in MCC. In this review, we describe the circulating biomarkers and discuss the technical challenges and the clinical relevance of liquid biopsy for these two skin malignancies.

2. Merkel Cell Carcinoma

MCC is a rare skin cancer that usually appears as a pink/red, rapidly growing skin nodule on UV-exposed areas, such as head, neck and upper limbs. Usually, it is characterized by aggressive behavior and high metastasis rate without specific location [3]. Despite the currently low (but rapidly increasing) incidence (0.7 per 100,000) [4][5][6], MCC is associated with shorter disease-free and OS and higher cancer-related death rates than melanoma. To date, two main different oncogenic pathways have been identified [7][8]. The first is related to UV exposure with high tumor mutational burden, while the second one is related to a ubiquitous DNA virus, Merkel Cell Polyomavirus (MCPyV). Although the involvement of this virus in MCC development has been clearly established, the underlying molecular mechanisms have not been fully characterized. MCPyV was first described in 2008 by Feng et al. [9], and is the first human polyomavirus clearly linked to a human cancer [10]. Moreover, its epidemiological link with immunosuppressive conditions, including chronic lymphocytic leukemia and solid organ transplantation, is well established [11][12].

The hypothesis that MCC originates from epidermal Merkel cells [13] is supported by some common features between Merkel and MCC cells, such as the presence of a cytokeratin network as a dot, and the expression of cytokeratin-20 and neuron-specific enolase [14][15]. However, alternative theories have been proposed, involving, for example, a common cell ancestor with B lymphocytes [16].

Besides these debates on MCC cellular origin [17], recent studies tried to better understand the mechanisms underlying this malignancy, notably the involvement of the MCPyV virus that is detected in 80% of cases [18][19][20]. Currently, it is known that MCPyV is first present in cells in an episomal conformation [21] and is subsequently integrated in the cell DNA.

As this tumor remains poorly understood, liquid biopsy might help to decipher its nature, the underlying mechanisms and might ensure a real-time follow-up of the disease and of its response to different treatments. Research on this topic is in its early days, but some studies have already investigated different circulating biomarkers in MCC (Table 1).

Table 1. Studies on liquid biopsy in Merkel cell carcinoma.

Study

Title

Bio-

Marker

Inclusion Criteria

n

Detection Method

Prognosis Relevance

Ref

Blom et al. (2014)

Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma

CTCs

Stage I – IV

34 

CellSearch—Epithelial kit

CTCs associated with survival, prediction of treatment response, shorter OS and reflect disease burden.

[22]

Gaiser et al, (2015)

Evaluating blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as Merkel cell carcinoma biomarkers

CTCs

Stage I–IV

30

Maintrac

Correlation between CTC detection and disease outcomes.

[23]

Samimi et al. (2016)

Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma

Anti-MCPyV-antibody

Stage I–IV

143

ELISA

Basal level of anti-VP1 antibodies used as prognostic marker. Anti-T‐antigen antibodies are marker of disease recurrence or progression if detected >12 months after diagnosis

[24]

Fan et al. (2018)

Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinoma

miRNA

Stage I–IV

102

RT-qPCR

Circulating miR-375 is a useful biomarker for tumor burden, therapy monitoring and follow-up of patients with MCC.

[25]

Riethdorf et al. (2019)

Detection and characterization of circulating tumor cells in patients with Merkel cell carcinoma

CTCs

Stage I–IV

51

CellSearch—CXC kit

Correlations between CTC counts and MCC aggressiveness.

[26]

Boyer et al. (2020)

Circulating tumor cell detection and polyomavirus status in Merkel cell carcinoma

CTCs

Stage I­–IV

19

•CellSearch—CTC kit

•RosetteSep/DEPArray

CTC presence associated with tumor stage and number of organs with metastases.

[27]

CTC: circulating tumor cell, OS: Overall Survival, MCPyV: Merkel Cell Polyomavirus, ctDNA: circulating tumor DNA, miRNA: microRNA, ELISA: Enzyme-linked immunosorbent assay, RT-qPCR: Reverse-transcriptase Polymerase Chain Reaction.

2.1. CTCs and Circulating miRNAs

The few studies on this topic show how little is known about MCC. Moreover, the existing data concern small patient cohorts, due to MCC rarity. Nevertheless, some circulating biomarkers might help to better understand MCC. CTCs have been associated with patient survival and MCC aggressiveness [28], and high miRNA-375 concentration in plasma with tumor burden [29]. Therefore, they are candidate biomarkers for MCC follow-up. In patients with MCC, CTCs are usually detected using the CellSearch® system [30][31][32], based on the positive enrichment of EpCAM-expressing cells. A new CTC detection method based on negative enrichment was investigated by Boyer et al.. They evaluated CTC number to follow the disease course, and also characterized MCC CTCs (e.g., PD-L1 status). They found that CTC detection was associated with the cancer stage. The few studies on circulating miRNA in MCC used RT-qPCR as detection technology [33], like for other cancers [34][35]. The MCC miRNome has been investigated mostly in formalin-fixed paraffin-embedded tumor samples [36][37], and the miRNAs identified as MCC-specific could now be evaluated in liquid biopsies.

2.2. Exosomes

Exosomes are small vesicles secreted by different types of cells under the influence of cellular conditions and environment [38]. They might be used as an MCC biomarker. However, they have been investigated only in MCC cell lines and more data are needed. These preliminary studies suggest that exosomes might be a good candidate biomarker. Indeed, they showed that MCC-derived exosomes transport proteins linked to cancer, such as LDH and factors implicated in the p38 MAPK and Wnt signaling pathways. Importantly, these proteins were detected independently of the cell line MCPyV status [38], thus they could be used to monitor all patients with MCC.

2.3. Anti-MCPyV Antibodies

The presence of MCPyV in most MCC specimens and the higher incidence in immune-deficient patients indicate the implication of the immune system in MCC. The large T (LT) and small T (sT) antigens of MCPyV are involved in oncogenesis, for example their presence has been linked to cell cycle disturbance or viral replication. Moreover, LT is required for the survival of cancer cell lines [39]. Titration of the VP1 capsid protein of MCPyV has been used as a circulating biomarker of the viral load in patients. In these studies, high levels of anti-VP1 and anti-sT antibodies in blood was correlated with better outcome [40], and anti-LT antibodies are a prognostic factor of recurrence if they are detected more than one year after diagnosis.

2.4. Immunotherapy

An immunohistochemical analysis of MCC specimens found that many cancer cells express PD-L1, particularly when they are in close proximity to infiltrating immune cells [41]. This mechanism is used by MCC cells to escape immunity. Specifically, cancer cells express PD-L1 at their surface, and its interaction with PD-1 at the surface of immune cells will block their identification as cancer cells. This phenomenon has been highlighted in many different cancers and is one of the immune checkpoints targeted by immunotherapy. Recently, immunotherapy based on PD-1/PD-L1 inhibition [42][43][44] has been approved by the US FDA for patients with metastatic MCC. This therapy has already been used in other cancers for some years [45] and is also efficient in patients with metastatic MCC, although the response rate remains unsatisfactory [46]. Detection of PD-L1 at the surface of CTCs could help for MCC patient management. This emphasizes the need of better understanding this disease to develop more appropriate treatments.

A query of the ClinicalTrials.gov database with the keyword “Merkel cell carcinoma” in November 2019 did not retrieve any ongoing study on circulating biomarkers in MCC. Most of the listed studies were testing new treatments.

2.5. Conclusion

Liquid biopsy in MCC could be of clinical interest for patient management, as suggested by the correlation of CTCs and circulating miRNAs with disease outcomes and tumor burden. However, more research must be done in larger cohorts and on different potential candidate biomarkers.

References

  1. Leiter, U.; Eigentler, T.; Garbe, C. Epidemiology of skin cancer. Adv. Exp. Med. Biol. 2014, 810, 120–140, doi:10.1007/978-1-4939-0437-2_7.
  2. Houben, R.; Schrama, D.; Becker, J.C. Molecular pathogenesis of Merkel cell carcinoma. Exp. Dermatol. 2009, 18, 193–198, doi:10.1111/j.1600-0625.2009.00853.x.
  3. Kouzmina, M.; Koljonen, V.; Leikola, J.; Bohling, T.; Lantto, E. Frequency and locations of systemic metastases in Merkel cell carcinoma by imaging. Acta Radiol. Open 2017, 6, 2058460117700449, doi:10.1177/2058460117700449.
  4. Paulson, K.G.; Park, S.Y.; Vandeven, N.A.; Lachance, K.; Thomas, H.; Chapuis, A.G.; Harms, K.L.; Thompson, J.A.; Bhatia, S.; Stang, A.; et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J. Am. Acad. Dermatol. 2018, 78, 457–463, doi:10.1016/j.jaad.2017.10.028.
  5. Hodgson, N.C. Merkel cell carcinoma: Changing incidence trends. J. Surg. Oncol 2005, 89, 1–4, doi:10.1002/jso.20167.
  6. Reichgelt, B.A.; Visser, O. Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993–2007. Eur. J. Cancer 2011, 47, 579–585, doi:10.1016/j.ejca.2010.11.002.
  7. Becker, J.C.; Stang, A.; DeCaprio, J.A.; Cerroni, L.; Lebbe, C.; Veness, M.; Nghiem, P. Merkel cell carcinoma. Nat. Rev. Dis. Primers 2017, 3, 17077, doi:10.1038/nrdp.2017.77.
  8. Carter, M.D.; Gaston, D.; Huang, W.Y.; Greer, W.L.; Pasternak, S.; Ly, T.Y.; Walsh, N.M. Genetic profiles of different subsets of Merkel cell carcinoma show links between combined and pure MCPyV-negative tumors. Hum. Pathol. 2018, 71, 117–125, doi:10.1016/j.humpath.2017.10.014.
  9. Feng, H.; Shuda, M.; Chang, Y.; Moore, P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008, 319, 1096–1100, doi:10.1126/science.1152586.
  10. Chang, Y.; Moore, P.S. Merkel cell carcinoma: A virus-induced human cancer. Annu. Rev. Pathol. 2012, 7, 123–144, doi:10.1146/annurev-pathol-011110-130227.
  11. Ritter, C.; Fan, K.; Paschen, A.; Reker Hardrup, S.; Ferrone, S.; Nghiem, P.; Ugurel, S.; Schrama, D.; Becker, J.C. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci. Rep. 2017, 7, 2290, doi:10.1038/s41598-017-02608-0.
  12. Popovic, L.; Jovanovic, D.; Petrovic, D.; Nikin, Z.; Matovina-Brko, G.; Trifunovic, J.; Kolarov-Bjelobrk, I. Concurrent chronic lymphocytic leukemia and merkel cell carcinoma in primary skin tumor and metastatic lymph node. Indian J. Hematol. Blood Transfus. 2014, 30, 422–424, doi:10.1007/s12288-014-0447-4.
  13. Maricich, S.M.; Wellnitz, S.A.; Nelson, A.M.; Lesniak, D.R.; Gerling, G.J.; Lumpkin, E.A.; Zoghbi, H.Y. Merkel cells are essential for light-touch responses. Science 2009, 324, 1580–1582, doi:10.1126/science.1172890.
  14. Kervarrec, T.; Samimi, M.; Guyetant, S.; Sarma, B.; Cheret, J.; Blanchard, E.; Berthon, P.; Schrama, D.; Houben, R.; Touze, A. Histogenesis of Merkel Cell Carcinoma: A Comprehensive Review. Front. Oncol. 2019, 9, 451, doi:10.3389/fonc.2019.00451.
  15. Yang, A.; Cordoba, C.; Cheung, K.; Konya, J. Merkel cell carcinoma in situ: New insights into the cells of origin. Australas J. Dermatol. 2019, 10.1111/ajd.13068, doi:10.1111/ajd.13068.
  16. Sauer, C.M.; Haugg, A.M.; Chteinberg, E.; Rennspiess, D.; Winnepenninckx, V.; Speel, E.J.; Becker, J.C.; Kurz, A.K.; Zur Hausen, A. Reviewing the current evidence supporting early B-cells as the cellular origin of Merkel cell carcinoma. Crit. Rev. Oncol. Hematol. 2017, 116, 99–105, doi:10.1016/j.critrevonc.2017.05.009.
  17. Sunshine, J.C.; Jahchan, N.S.; Sage, J.; Choi, J. Are there multiple cells of origin of Merkel cell carcinoma? Oncogene 2018, 37, 1409–1416, doi:10.1038/s41388-017-0073-3.
  18. Cheng, J.; Park, D.E.; Berrios, C.; White, E.A.; Arora, R.; Yoon, R.; Branigan, T.; Xiao, T.; Westerling, T.; Federation, A.; et al. Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. PLoS Pathog. 2017, 13, e1006668, doi:10.1371/journal.ppat.1006668.
  19. Verhaegen, M.E.; Mangelberger, D.; Harms, P.W.; Eberl, M.; Wilbert, D.M.; Meireles, J.; Bichakjian, C.K.; Saunders, T.L.; Wong, S.Y.; Dlugosz, A.A. Merkel Cell Polyomavirus Small T Antigen Initiates Merkel Cell Carcinoma-like Tumor Development in Mice. Cancer Res. 2017, 77, 3151–3157, doi:10.1158/0008-5472.CAN-17-0035.
  20. Sastre-Garau, X.; Peter, M.; Avril, M.F.; Laude, H.; Couturier, J.; Rozenberg, F.; Almeida, A.; Boitier, F.; Carlotti, A.; Couturaud, B.; et al. Merkel cell carcinoma of the skin: Pathological and molecular evidence for a causative role of MCV in oncogenesis. J. Pathol. 2009, 218, 48–56, doi:10.1002/path.2532.
  21. Laude, H.C.; Jonchere, B.; Maubec, E.; Carlotti, A.; Marinho, E.; Couturaud, B.; Peter, M.; Sastre-Garau, X.; Avril, M.F.; Dupin, N.; et al. Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma. PLoS Pathog. 2010, 6, e1001076, doi:10.1371/journal.ppat.1001076.
  22. Blom, A.; Bhatia, S.; Pietromonaco, S.; Koehler, K.; Iyer, J.G.; Nagase, K.; Paulson, K.; Sabath, D.E.; Nghiem, P. Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma. J. Am. Acad. Dermatol. 2014, 70, 449–455, doi:10.1016/j.jaad.2013.10.051.
  23. Gaiser, M.R.; Daily, K.; Hoffmann, J.; Brune, M.; Enk, A.; Brownell, I. Evaluating blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as Merkel cell carcinoma biomarkers. Oncotarget 2015, 6, 26472–26482, doi:10.18632/oncotarget.4500.
  24. Samimi, M.; Molet, L.; Fleury, M.; Laude, H.; Carlotti, A.; Gardair, C.; Baudin, M.; Gouguet, L.; Maubec, E.; Avenel-Audran, M.; et al. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br. J. Dermatol. 2016, 174, 813–822, doi:10.1111/bjd.14313.
  25. Fan, K.; Ritter, C.; Nghiem, P.; Blom, A.; Verhaegen, M.E.; Dlugosz, A.; Odum, N.; Woetmann, A.; Tothill, R.W.; Hicks, R.J.; et al. Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. Clin. Cancer Res. 2018, 24, 5873–5882, doi:10.1158/1078-0432.CCR-18-1184.
  26. Riethdorf, S.; Hildebrandt, L.; Heinzerling, L.; Heitzer, E.; Fischer, N.; Bergmann, S.; Mauermann, O.; Waldispuhl-Geigl, J.; Coith, C.; Schon, G.; et al. Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma. Clin. Chem. 2019, doi:10.1373/clinchem.2018.297028.
  27. Boyer, M.; Cayrefourcq, L.; Garima, F.; Foulongne, V.; Dereure, O.; Alix-Panabieres, C. Circulating Tumor Cell Detection and Polyomavirus Status in Merkel Cell Carcinoma. Sci. Rep. 2020, 10, 1612, doi:10.1038/s41598-020-58572-9.
  28. Greenberg, E.S.; Chong, K.K.; Huynh, K.T.; Tanaka, R.; Hoon, D.S. Epigenetic biomarkers in skin cancer. Cancer Lett. 2014, 342, 170–177, doi:10.1016/j.canlet.2012.01.020.
  29. Konstatinell, A.; Coucheron, D.H.; Sveinbjornsson, B.; Moens, U. MicroRNAs as Potential Biomarkers in Merkel Cell Carcinoma. Int. J. Mol. Sci. 2018, 19, doi:10.3390/ijms19071873.
  30. Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W.; et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351, 781–791, doi:10.1056/NEJMoa040766.
  31. Cohen, S.J.; Punt, C.J.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.; Mitchell, E.; Miller, M.C.; et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 3213–3221, doi:10.1200/JCO.2007.15.8923.
  32. de Bono, J.S.; Scher, H.I.; Montgomery, R.B.; Parker, C.; Miller, M.C.; Tissing, H.; Doyle, G.V.; Terstappen, L.W.; Pienta, K.J.; Raghavan, D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008, 14, 6302–6309, doi:10.1158/1078-0432.CCR-08-0872.
  33. Abraham, K.J.; Zhang, X.; Vidal, R.; Pare, G.C.; Feilotter, H.E.; Tron, V.A. Roles for miR-375 in Neuroendocrine Differentiation and Tumor Suppression via Notch Pathway Suppression in Merkel Cell Carcinoma. Am. J. Pathol. 2016, 186, 1025–1035, doi:10.1016/j.ajpath.2015.11.020.
  34. Uso, M.; Jantus-Lewintre, E.; Sirera, R.; Bremnes, R.M.; Camps, C. miRNA detection methods and clinical implications in lung cancer. Future Oncol. 2014, 10, 2279–2292, doi:10.2217/fon.14.93.
  35. Kappel, A.; Keller, A. miRNA assays in the clinical laboratory: Workflow, detection technologies and automation aspects. Clin. Chem. Lab. Med. 2017, 55, 636–647, doi:10.1515/cclm-2016-0467.
  36. Kumar, S.; Xie, H.; Shi, H.; Gao, J.; Juhlin, C.C.; Bjornhagen, V.; Hoog, A.; Lee, L.; Larsson, C.; Lui, W.O. Merkel cell polyomavirus oncoproteins induce microRNAs that suppress multiple autophagy genes. Int. J. Cancer 2019, 10.1002/ijc.32503, doi:10.1002/ijc.32503.
  37. Ning, M.S.; Kim, A.S.; Prasad, N.; Levy, S.E.; Zhang, H.; Andl, T. Characterization of the Merkel Cell Carcinoma miRNome. J. Skin Cancer 2014, 2014, 289548, doi:10.1155/2014/289548.
  38. Konstantinell, A.; Bruun, J.A.; Olsen, R.; Aspar, A.; Skalko-Basnet, N.; Sveinbjornsson, B.; Moens, U. Secretomic analysis of extracellular vesicles originating from polyomavirus-negative and polyomavirus-positive Merkel cell carcinoma cell lines. Proteomics 2016, 16, 2587–2591, doi:10.1002/pmic.201600223.
  39. Samimi, M. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. Am. J. Clin. Dermatol. 2019, doi:10.1007/s40257-019-00427-9.
  40. Paulson, K.G.; Lewis, C.W.; Redman, M.W.; Simonson, W.T.; Lisberg, A.; Ritter, D.; Morishima, C.; Hutchinson, K.; Mudgistratova, L.; Blom, A.; et al. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer 2017, 123, 1464–1474, doi:10.1002/cncr.30475.
  41. Mitteldorf, C.; Berisha, A.; Tronnier, M.; Pfaltz, M.C.; Kempf, W. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. J. Cutan. Pathol. 2017, 44, 740–746, doi:10.1111/cup.12973.
  42. Giraldo, N.A.; Nguyen, P.; Engle, E.L.; Kaunitz, G.J.; Cottrell, T.R.; Berry, S.; Green, B.; Soni, A.; Cuda, J.D.; Stein, J.E.; et al. Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J. Immunother Cancer 2018, 6, 99, doi:10.1186/s40425-018-0404-0.
  43. Barkdull, S.; Brownell, I. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma. Cancer Biol. Ther. 2017, 18, 937–939, doi:10.1080/15384047.2017.1394552.
  44. Gaiser, M.R.; Bongiorno, M.; Brownell, I. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. Expert Rev. Clin. Pharmacol. 2018, 11, 345–359, doi:10.1080/17512433.2018.1445966.
  45. Hamanishi, J.; Mandai, M.; Matsumura, N.; Abiko, K.; Baba, T.; Konishi, I. PD-1/PD-L1 blockade in cancer treatment: Perspectives and issues. Int. J. Clin. Oncol. 2016, 21, 462–473, doi:10.1007/s10147-016-0959-z.
  46. Shirley, M. Avelumab: A Review in Metastatic Merkel Cell Carcinoma. Target. Oncol. 2018, 13, 409–416, doi:10.1007/s11523-018-0571-4.
More
Information
Subjects: Oncology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
View Times: 368
Revisions: 3 times (View History)
Update Date: 25 Feb 2021
1000/1000